Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. (Q37964490)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22139135%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22139135%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22139135%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Chris Corrigan

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22139135%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Andrew J. Beavil

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22139135%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Hannah J Gould

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22139135%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Sophia N Karagiannis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22139135%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Debra H Josephs

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22139135%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Panagiotis Karagiannis

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22139135%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Amy E Gilbert

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22139135%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Louise Saul

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22139135%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Sarah M Rudman

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22139135%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Tihomir Dodev

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22139135%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Alexander Koers

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22139135%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

James F Spicer

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22139135%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Frank O Nestle

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22139135%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

3 December 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22139135%20AND%20SRC:MED&resulttype=core&format=json

Cancer Immunology, Immunotherapy

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22139135%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

61

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22139135%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22139135%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

1547-1564

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22139135%20AND%20SRC:MED&resulttype=core&format=json

Monoclonal antibodies: versatile platforms for cancer immunotherapy

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Research and development of next generation of antibody-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

The history and rationale for monoclonal antibodies in the treatment of hematologic malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Monoclonal antibodies in solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Therapeutic antibodies: current state and future trends--is a paradigm change coming soon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

The future of anti-CD20 monoclonal antibodies: are we making progress?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

IgA antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Monoclonal antibody mechanisms of action in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

In pursuit of new anti-angiogenic therapies for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

New antibody conjugates in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Engineered therapeutic antibodies with improved effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Regulation of IgE homeostasis, and the identification of potential targets for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Tumors and inflammatory infiltrates: friends or foes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

The Human Low Affinity Fcγ Receptors IIa, IIb, and III Bind IgG with Fast Kinetics and Distinct Thermodynamic Properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

IgE in allergy and asthma today

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

The biology of IGE and the basis of allergic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Expression of functional high affinity immunoglobulin E receptors (Fc epsilon RI) on monocytes of atopic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

The structure of human CD23 and its interactions with IgE and CD21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Quantifying aggregation of IgE-FcepsilonRI by multivalent antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

The human immune response during cutaneous leishmaniasis: NO problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

The killing of Leishmania major by human macrophages is mediated by nitric oxide induced after ligation of the Fc epsilon RII/CD23 surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Mouse CD23 regulates monocyte activation through an interaction with the adhesion molecule CD11b/CD18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Two species of human Fc epsilon receptor II (Fc epsilon RII/CD23): tissue-specific and IL-4-specific regulation of gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Immune infiltration in human tumors: a prognostic factor that should not be ignored

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Distinct role of macrophages in different tumor microenvironments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Role of infiltrated leucocytes in tumour growth and spread

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Folate receptor alpha as a tumor target in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Overexpression of folate binding protein in ovarian cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

A novel monoclonal antibody for detection of folate receptor alpha in paraffin-embedded tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Distribution of OV-TL 3 and MOv18 in normal and malignant ovarian tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Farletuzumab in epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Influence on immunoreactive folate-binding proteins of extracellular folate concentration in cultured human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Purified membrane and soluble folate binding proteins from cultured KB cells have similar amino acid compositions and molecular weights but differ in fatty acid acylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Recombinant human monoclonal igA antibody against CEA to recruit neutrophils to CEA-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Involvement of NK cells against tumors and parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

High-affinity immunoglobulin E receptor (Fc epsilon RI)-bearing eosinophils, mast cells, macrophages and Langerhans' cells in allergen-induced late-phase cutaneous reactions in atopic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Growth inhibition of murine mammary carcinoma by monoclonal IgE antibodies specific for the mammary tumor virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Total and functional parasite specific IgE responses in Plasmodium falciparum-infected patients exhibiting different clinical status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

The mast cell: an antenna of the microenvironment that directs the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Why could passive Immunoglobulin E antibody therapy be safe in clinical oncology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Histamine and tryptase levels in patients with acute allergic reactions: An emergency department-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

An assessment of peripheral immunity in patients with sarcoidosis using measurements of serum vitamin D3, cytokines and soluble CD23.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

A soluble form of the high affinity IgE receptor, Fc-epsilon-RI, circulates in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Risk assessment in anaphylaxis: current and future approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

AllergoOncology: the role of IgE-mediated allergy in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

Expression of high-affinity IgE receptors (FcϵRI) on peripheral blood basophils, monocytes, and eosinophils in atopic and nonatopic subjects: Relationship to total serum IgE concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1162-8

10.1007/S00262-011-1162-8

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22139135%20AND%20SRC:MED&resulttype=core&format=json

release_wiklhzgtbfes3pfbbkqsx56jeu

17 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wiklhzgtbfes3pfbbkqsx56jeu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference